scholarly journals Visceral and subcutaneous adipose tissue FDG uptake by PET/CT in metabolically healthy obese subjects

Obesity ◽  
2014 ◽  
Vol 23 (2) ◽  
pp. 286-289 ◽  
Author(s):  
Adriana L. Oliveira ◽  
Debora C. Azevedo ◽  
Miriam A. Bredella ◽  
Takara L. Stanley ◽  
Martin Torriani
Keyword(s):  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Fdg Uptake ◽  
Metabolically Healthy Obese ◽  
Pet Ct ◽  
Obese Subjects ◽  
Healthy Obese ◽  
Metabolically Healthy ◽  
Subcutaneous Adipose

Abstract 17843: Visceral Adipose Tissue Secretion of Adiponectin Decreases with Increased Body Mass Index

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Lenore R Rengel ◽  
Brittaney Obi ◽  
Jon Gould ◽  
Matthew Goldblatt ◽  
Andrew Kastenmeier ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Visceral Adipose Tissue ◽  
Metabolic Health ◽  
Metabolically Healthy Obese ◽  
Obese Subjects ◽  
Healthy Obese ◽  
Metabolically Healthy ◽  
Visceral Adipose ◽  
Subcutaneous Adipose

Introduction: Peripheral adiposity is associated with better metabolic health and higher plasma adiponectin (ADPN) levels. Since ADPN is secreted mainly by adipose tissue (AT), it is intriguing that higher visceral adipose tissue (VAT) is associated with lower ADPN levels and poor metabolic health. Hypothesis: We hypothesized that various AT depots differ in their ability to secrete ADPN. Methods: Paired AT samples (VAT and subcutaneous adipose tissue (SAT)) were collected from 19 subjects (10 women, 15 obese) undergoing elective abdominal surgery. The samples were cultured and the supernatant was collected after 24 hours. ADPN levels released into the supernatant from VAT and SAT were measured using multiplex methods. Subjects were defined as obese or non-obese (NO) based on BMI > or ≤ 30kg/m2 respectively. Obese subjects were further classified as metabolically unhealthy obese (MUO) or metabolically healthy obese (MHO) based on presence or absence of type 2 diabetes mellitus, hypertension, or cardiovascular disease at the time of surgery. Results: Mean ADPN secretion levels from SAT and VAT were similar in NO subjects (17.3 ± 3.4 vs. 9.8 ± 13.0 ng/mL/mg, p=0.5) whereas the mean ADPN secretion was lower from VAT among obese subjects (15.9 ± 0.8 vs. 4.5 ± 0.2 ng/mL/mg, p=0.0002). ADPN secretion decreased from VAT (r=-0.16) and increased from SAT (r=0.33) with increased BMI (Fig.1). When MHO and MUO were compared, ADPN secretion from VAT in MHO was reduced only slightly (16.1 ± 8.2 vs. 4.0 ± 2.0 ng/mL/mg, p=0.07) whereas ADPN secretion was significantly reduced in MUO (15.9 ± 5.3 vs. 4.7 ± 4.6 ng/mL/mg, p=0.003). Conclusions: Reduced ADPN secretion from VAT in subjects with increasing BMI may explain lower circulating ADPN levels in obese individuals. Higher ADPN production from SAT and the relatively preserved secretion of ADPN from VAT may explain metabolic health in some obese individuals. Futures studies will help identify factors that control ADPN secretion from AT.

scholarly journals RANTES release by human adipose tissue in vivo and evidence for depot-specific differences

2009 ◽  
Vol 296 (6) ◽  
pp. E1262-E1268 ◽  
Author(s):  
Rana Madani ◽  
Kalypso Karastergiou ◽  
Nicola C. Ogston ◽  
Nazar Miheisi ◽  
Rahul Bhome ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Epicardial Adipose Tissue ◽  
Ex Vivo ◽  
Human Adipose Tissue ◽  
Fat Pad ◽  
Obese Subjects ◽  
Subcutaneous Adipose ◽  
Circulating Levels

Obesity is associated with elevated inflammatory signals from various adipose tissue depots. This study aimed to evaluate release of regulated on activation, normal T cell expressed and secreted (RANTES) by human adipose tissue in vivo and ex vivo, in reference to monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) release. Arteriovenous differences of RANTES, MCP-1, and IL-6 were studied in vivo across the abdominal subcutaneous adipose tissue in healthy Caucasian subjects with a wide range of adiposity. Systemic levels and ex vivo RANTES release were studied in abdominal subcutaneous, gastric fat pad, and omental adipose tissue from morbidly obese bariatric surgery patients and in thoracic subcutaneous and epicardial adipose tissue from cardiac surgery patients without coronary artery disease. Arteriovenous studies confirmed in vivo RANTES and IL-6 release in adipose tissue of lean and obese subjects and release of MCP-1 in obesity. However, in vivo release of MCP-1 and RANTES, but not IL-6, was lower than circulating levels. Ex vivo release of RANTES was greater from the gastric fat pad compared with omental ( P = 0.01) and subcutaneous ( P = 0.001) tissue. Epicardial adipose tissue released less RANTES than thoracic subcutaneous adipose tissue in lean ( P = 0.04) but not obese subjects. Indexes of obesity correlated with epicardial RANTES but not with systemic RANTES or its release from other depots. In conclusion, RANTES is released by human subcutaneous adipose tissue in vivo and in varying amounts by other depots ex vivo. While it appears unlikely that the adipose organ contributes significantly to circulating levels, local implications of this chemokine deserve further investigation.

scholarly journals Erratum: Permanence of molecular features of obesity in subcutaneous adipose tissue of ex-obese subjects

2013 ◽  
Vol 37 (6) ◽  
pp. 892-892 ◽  
Author(s):  
R Cancello ◽  
A Zulian ◽  
D Gentilini ◽  
M Mencarelli ◽  
A Della Barba ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Molecular Features ◽  
Obese Subjects ◽  
Subcutaneous Adipose

Abstract MP81: Differences in Body Composition Between Metabolically Healthy Obese and Metabolically Abnormal Obese Phenotypes

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Sarah M Camhi ◽  
Peter T Katzmarzyk
Keyword(s):  
Risk Factors ◽  
Body Composition ◽  
Adipose Tissue ◽  
Bone Mineral ◽  
Fat Mass ◽  
Lean Mass ◽  
Cardiometabolic Risk ◽  
Metabolically Healthy Obese ◽  
Healthy Obese ◽  
Metabolically Healthy

Purpose: Studies of body composition between metabolically healthy obese (MHO) and metabolically abnormal obese (OA) cardiometabolic profiles have been limited to mostly small sample sizes and postmenopausal women. Thus, the purpose is to determine whether measures of body composition differ between MHO and OA using men and women across a wide age range. Methods: The sample included 395 obese (≥30 kg/m 2 ) adults (66% women; 62% white, 38% African American) from the Pennington Center Longitudinal Study, 18-68 years of age (mean±SD: 40.6±13.2). Adults were classified as OA (≥2 cardiometabolic risk factors: blood pressure ≥130/85 mmHg; triglycerides ≥150 mg/dL, high density lipoprotein cholesterol men <40, women <50 mg/dL; fasting glucose ≥100 mg/dL) or MHO (<2 cardiometabolic risk factors). Whole-body bone mineral density (BMD; g/cm 2 ), bone mineral content (BMC; kg), percent body fat (%), fat mass (kg), lean mass (kg) and trunk adipose tissue mass (kg) were measured with dual-energy x-ray absorptiometry. Visceral (VAT; cm 2 ), subcutaneous (SAT; cm 2 ), and total abdominal adipose tissue (TAT; cm 2 ) were measured with computed tomography. Non-normally distributed variables were log transformed for analysis (lean mass, VAT, BMD and BMC) but means were reverse-transformed for presentation of results. Gender-specific general linear regression models (men: n=136; women: n=259) were used to determine differences in body composition between MHO (men: n=57; women n=153) and OA (men: n=79; women n=106) controlling for age, race, smoking status, and menopause status (in women). Results: In men, OA had greater fat mass (OA vs. MHO mean±SE; p-value for difference: 31.4±1.2 vs. 28.6±1.2 kg; p=0.02) and greater trunk adipose tissue (16.5±0.7 vs. 14.3±0.8 kg; p=0.002) compared with MHO, but no significant differences between MHO and OA profiles for BMD, BMC, % fat, lean mass, VAT, SAT, or TAT. Women with OA profiles had greater lean mass (54.4±1.0 vs. 51.5±1.0 kg; p<0.0001), greater VAT (119.4±1.1 vs. 95.7±1.1 cm 2 ; p<0.0001) and greater trunk adipose tissue (18.0±0.5 vs. 17.1±0.5 kg; p=0.03) when compared with MHO women, with no significant differences between MHO and OA for BMD, BMC, % fat, fat mass, SAT or TAT. Conclusion: OA and MHO cardiometabolic profiles are characterized by differences in body composition that vary by gender. Men have differences in overall and trunk adipose tissue while women have differences in lean mass and centralized fat (VAT and trunk). Future studies should confirm these results in different race and age groups.

Sign in / Sign up

Export Citation Format

Share Document